BioSpace News Archive

Drug Development

89bio Presents Additional Analysis of Phase 1b/2a NASH Study at the Annual ENDO 2021 ConferenceNew analysis shows BIO89-100 meaningfully reduces liver fat volume and liver volume in patients with NASH

89bio, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, announced additional positive data from its Phase 1b/2a study of BIO89-100, a long-acting glycoPEGylated FGF21 analog, in patients with nonalcoholic steatohepatitis.

March 20, 2021
·
4 min read
Drug Development

Chiasma Presents New Positive Data for MYCAPSSA from Phase 3 Trial MPOWERED™ for the Maintenance Treatment of Acromegaly at ENDO 2021

Data demonstrated patients taking MYCAPSSA had significant improvement in acromegaly related symptoms and patient reported outcomes after switching from iSRLs

March 20, 2021
·
11 min read
BioMidwest

Clarus Therapeutics Presents Positive Safety And Efficacy Data For JATENZO® (Testosterone Undecanoate) Oral Capsules, CIII At ENDO 2021, The Endocrine Society’s Annual Meeting

Data from a two-year study supports JATENZO as an effective long-term oral testosterone replacement therapy for hypogonadal men, maintaining normal testosterone levels with no evidence of liver toxicity

March 20, 2021
·
13 min read
Policy

Statement from the Chief Public Health Officer of Canada on March 20, 2021

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.

March 20, 2021
·
5 min read